Listen on the go
CORRECT!
Next question
touchHAEMATOLOGY touchHAEMATOLOGY

Trending Activities
Genetic Blood Disorders
CE/CME ACCREDITED
touchPANEL DISCUSSION
Contemporary insights on the management of sickle cell disease: Focus on complications and recent advances in therapy
Prof. Biree Andemariam, Prof. Modupe Idowu, Prof. Mark C Walters
Watch Time: 39 mins

Three experts discuss the management of complications of sickle cell disease, as well as recent advances in therapy.

Learning objectives
Learning Objectives
  • Summarize the various manifestations and multiple complications of SCD
  • Appraise the practical considerations for the multidisciplinary management of SCD complications
  • Interpret the clinical data for established and recently approved therapies for SCD and apply them to clinical practice
Myeloproliferative Disorders, Haematological Malignancies, Rare Diseases
CE/CME ACCREDITED
touchIN CONVERSATION
Optimizing outcomes of JAK inhibition in myelofibrosis: Practical considerations for the clinic
Dr Raajit Rampal, Prof. John Mascarenhas
Watch Time: 38 mins

Two haematologic oncologists discuss optimizing the use of JAK inhibitors for patients with myelofibrosis.

Learning objectives
Learning Objectives
  • Discuss considerations for selecting an appropriate JAK inhibitor in the first-line treatment of myelofibrosis
  • Plan strategies for managing side effects associated with JAK inhibition in patients with myelofibrosis
  • Evaluate management approaches following lack of treatment success with first-line JAK inhibitor treatment in patients with myelofibrosis

All Activities

View all IME activities

Genetic Blood Disorders
Watch Time: 39 mins
touchPANEL DISCUSSION
Contemporary insights on the management of sickle cell disease: Focus on complications and recent advances in therapy
CE/CME ACCREDITED Prof. Biree Andemariam, Prof. Modupe Idowu, Prof. Mark C Walters

Three experts discuss the management of complications of sickle cell disease, as well as recent advances in therapy.

Learning objectives
Learning Objectives
  • Summarize the various manifestations and multiple complications of SCD
  • Appraise the practical considerations for the multidisciplinary management of SCD complications
  • Interpret the clinical data for established and recently approved therapies for SCD and apply them to clinical practice
Myeloproliferative Disorders, Haematological Malignancies, Rare Diseases
Watch Time: 38 mins
touchIN CONVERSATION
Optimizing outcomes of JAK inhibition in myelofibrosis: Practical considerations for the clinic
CE/CME ACCREDITED Dr Raajit Rampal, Prof. John Mascarenhas

Two haematologic oncologists discuss optimizing the use of JAK inhibitors for patients with myelofibrosis.

Learning objectives
Learning Objectives
  • Discuss considerations for selecting an appropriate JAK inhibitor in the first-line treatment of myelofibrosis
  • Plan strategies for managing side effects associated with JAK inhibition in patients with myelofibrosis
  • Evaluate management approaches following lack of treatment success with first-line JAK inhibitor treatment in patients with myelofibrosis
Haematological Malignancies, Multiple Myeloma
Watch Time: 38 mins
touchPANEL DISCUSSION
Key considerations for treatment selection and sequencing in patients with RRMM: Lessons from real-life clinical practice
CE/CME ACCREDITED Dr Sarah Holstein, Dr Nikhil Munshi, Dr Noopur Raje

Watch three specialists discuss patient cases and share their insights on optimization of treatment selection and sequencing in relapsed/refractory multiple myeloma (RRMM).

Learning objectives
Learning Objectives
  • Interpret factors that must be balanced when choosing therapy for patients with RRMM who have relapsed following 1–3 prior lines of therapy
  • Evaluate alternative treatment strategies for patients with RRMM following >3 prior lines of therapy
  • Identify optimal sequencing strategies for patients with RRMM in both early- and later-line settings
Genetic Blood Disorders
Watch Time: 37 mins
touchPANEL DISCUSSION
Navigating pyruvate kinase deficiency today: How can the disease burden and unmet treatment needs be addressed?
CE/CME ACCREDITED Dr Rachael Grace, Dr Hanny Al-Samkari, Dr Ami J Shah

Three experts discuss the burden and clinical presentation of pyruvate kinase deficiency, as well as current and emerging therapeutic strategies.

Learning objectives
Learning Objectives
  • Recognize the signs and symptoms of PK deficiency and the burden of disease in affected patients
  • Evaluate established therapeutic strategies for PK deficiency and identify remaining unmet treatment needs
  • Describe novel and emerging therapeutic strategies for PK deficiency and how they may address current unmet needs
Watch Time: 34 mins
touchTALKS
What’s on the horizon for higher-risk MDS? An update on emerging novel agents
CE/CME ACCREDITED Dr David Sallman

Dr David Sallman reviews advances in HR-MDS management, including the mode of action and latest clinical data for emerging treatments.

Learning objectives
Learning Objectives
  • Recall the mechanisms of action for key emerging treatments for patients with HR-MDS
  • Describe the latest efficacy data for key emerging treatments for patients with HR-MDS
  • Discuss the safety profile of key emerging treatments for patients with HR-MDS
Watch Time: 25 mins
touchEXPERT OPINIONS
Getting personal: Individualizing therapy for cold agglutinin disease
CE/CME ACCREDITED Dr Catherine M Broome, Dr Ilene Ceil Weitz

Watch two experts give their perspectives on the recommended workup for a timely and accurate diagnosis, as well as the evolving treatment landscape, and the importance of individualizing therapy for patients with cold agglutinin disease.

Learning objectives
Learning Objectives
  • Outline strategies for the accurate diagnosis of cold agglutinin disease
  • Evaluate the current and emerging treatment options for patients with cold agglutinin disease using the latest data
  • Assess potential strategies for individualizing the treatment for patients with cold agglutinin disease
Watch Time: 32 mins
touchPANEL DISCUSSION
Understanding the immunopathogenesis of CAD: What are the implications of new and emerging therapies?
CE/CME ACCREDITED Prof. Morie Gertz, Prof. Bernd Jilma, Dr Shirley D'Sa

Watch three experts discuss the pathophysiology of cold agglutinin disease (CAD) and the steps needed for an accurate diagnosis. The panel goes on to discuss how emerging treatment options are changing the management of patients with primary CAD and the importance of tailoring treatment to improve outcomes. The discussion is guided by pre-canvassed questions provided by the haematological clinical community.

Learning objectives
Learning Objectives
  • Describe the immunopathogenesis of cold agglutinin disease (CAD) and implications for effective patient management
  • Appraise current and emerging treatment options for patients with CAD using the latest data
  • Evaluate strategies to individualize the treatment and management of patients with CAD
Multiple Myeloma
Watch Time: 34 mins
touchIN CONVERSATION
How can real-world evidence guide the management of elderly and frail patients with multiple myeloma?
CE/CME ACCREDITED Dr Faith Davies, Dr E Randolph Broun

A multiple myeloma expert and a community oncologist discuss real-world evidence for frail/elderly patients and its application in practice.

Learning objectives
Learning Objectives
  • Explain the role and importance of real-world evidence (RWE) in supporting clinical decision making
  • Outline the key RWE related to the treatment of elderly and frail patients with multiple myeloma
  • Discuss the management of elderly and frail patients with multiple myeloma in clinical practice
Watch Time: 36 mins
touchPANEL DISCUSSION
Keeping pace with the evolving treatment paradigm for relapsed/refractory multiple myeloma: Earlier use of novel agents
CE/CME ACCREDITED Dr Nina Shah, Dr Cristina Gasparetto, Prof. Xavier Leleu

Three international experts discuss how novel agents approved for early lines of therapy are changing the landscape of RRMM treatment.

Learning objectives
Learning Objectives
  • Recall the role of novel therapies earlier in the treatment pathway for RRMM
  • Discuss the trials utilizing novel agents earlier in the treatment pathway for RRMM
  • Use appropriate supportive care measures when initiating patients with RRMM on a novel agent
Multiple Myeloma
Watch Time: 33 mins
touchPANEL DISCUSSION
Improving outcomes in multiple myeloma with new treatment targets
CE/CME ACCREDITED Prof. Joseph Mikhael, Dr Cristina Gasparetto, Dr Elena Zamagni

Watch a panel of experts discuss how novel targeted therapies are changing the treatment paradigm for multiple myeloma to achieve the best outcomes for patients.

Learning objectives
Learning Objectives
  • Recall the mechanisms of action and data for relapsed/refractory multiple myeloma treatments with novel agents
  • Discuss the adverse event (AE) profiles of treatments with novel targets and how AEs could be managed in clinical practice
  • Describe the possible role of agents with novel targets earlier in the multiple myeloma treatment pathway
IME
CME activities are developed by touchIME for touchHAEMATOLOGY.

Our education resources are developed in collaboration with our well established peer-reviewed medical journals, our Editorial Board members and partnerships with major medical societies, with a clear commitment to high-quality independent education.

Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72